Cargando…
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients offers...
Autores principales: | Schaefer, Jordan K., McBane, Robert D., Wysokinski, Waldemar E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742513/ https://www.ncbi.nlm.nih.gov/pubmed/26658769 http://dx.doi.org/10.1007/s00277-015-2566-x |
Ejemplares similares
-
Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation
por: Wysokinski, Waldemar E., et al.
Publicado: (2020) -
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021) -
Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007) -
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016) -
Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)